• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Is There an Extra Benefit of Adding Neoadjuvant Radiotherapy to Chemotherapy in Patients with (Borderline) Resectable Pancreatic Cancer?

作者信息

Yun Won-Gun, Jang Jin-Young

机构信息

Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

出版信息

Ann Surg Oncol. 2025 Apr;32(4):2859-2860. doi: 10.1245/s10434-024-16829-x. Epub 2025 Jan 15.

DOI:10.1245/s10434-024-16829-x
PMID:39812917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11882714/
Abstract
摘要

相似文献

1
ASO Author Reflections: Is There an Extra Benefit of Adding Neoadjuvant Radiotherapy to Chemotherapy in Patients with (Borderline) Resectable Pancreatic Cancer?ASO作者反思：对于（临界可切除的）胰腺癌患者，在化疗中添加新辅助放疗是否有额外益处？
Ann Surg Oncol. 2025 Apr;32(4):2859-2860. doi: 10.1245/s10434-024-16829-x. Epub 2025 Jan 15.
2
ASO Author Reflections: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer: Is Combined Radiotherapy Necessary?ASO作者反思：可切除边缘胰腺癌的新辅助治疗：联合放疗是否必要？
Ann Surg Oncol. 2019 Jun;26(6):1637-1638. doi: 10.1245/s10434-019-07245-7. Epub 2019 Feb 19.
3
ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement.ASO作者反思：关于新辅助化疗治疗伴有动脉侵犯的可切除边缘胰腺癌的新证据
Ann Surg Oncol. 2023 Jan;30(1):203-204. doi: 10.1245/s10434-022-12584-z. Epub 2022 Sep 21.
4
ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?ASO作者反思：可切除及边界可切除胰头腺癌的新辅助治疗：FOLFIRINOX方案是否优于吉西他滨/纳米白蛋白结合型紫杉醇？
Ann Surg Oncol. 2018 Dec;25(Suppl 3):808-809. doi: 10.1245/s10434-018-6833-7. Epub 2018 Oct 8.
5
ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.ASO作者反思：吉西他滨联合白蛋白结合型紫杉醇新辅助化疗对可切除边缘性胰腺癌手术结局的影响
Ann Surg Oncol. 2019 Dec;26(Suppl 3):739-740. doi: 10.1245/s10434-019-07857-z. Epub 2019 Sep 19.
6
Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer.化疗后新辅助放疗的疗效以及边缘可切除和可切除胰腺癌放疗至手术的最佳间隔时间
Ann Surg Oncol. 2025 Apr;32(4):2819-2829. doi: 10.1245/s10434-024-16743-2. Epub 2025 Jan 14.
7
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal.ASO作者反思：可切除边缘和局部晚期胰腺癌的化疗方案——手术是关键。
Ann Surg Oncol. 2023 Jul;30(7):4429-4430. doi: 10.1245/s10434-023-13484-6. Epub 2023 Apr 19.
8
ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes.ASO作者反思：接受胰十二指肠切除术的可切除和边界可切除胰腺导管腺癌患者的新辅助放化疗改变身体成分，影响长期预后。
Ann Surg Oncol. 2023 Apr;30(4):2469-2470. doi: 10.1245/s10434-022-13024-8. Epub 2022 Dec 25.
9
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.总新辅助 FOLFIRINOX 对比新辅助吉西他滨为基础的放化疗和辅助吉西他滨治疗可切除和交界可切除胰腺癌（PREOPANC-2 试验）：一项全国多中心随机对照试验的研究方案。
BMC Cancer. 2021 Mar 23;21(1):300. doi: 10.1186/s12885-021-08031-z.
10
ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologically Borderline-Resectable.ASO作者反思：与异常右肝动脉有肿瘤接触的胰腺癌应被视为技术上可切除但肿瘤学上接近可切除。
Ann Surg Oncol. 2022 Aug;29(8):4989-4990. doi: 10.1245/s10434-022-11639-5. Epub 2022 Apr 21.

本文引用的文献

1
Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer.化疗后新辅助放疗的疗效以及边缘可切除和可切除胰腺癌放疗至手术的最佳间隔时间
Ann Surg Oncol. 2025 Apr;32(4):2819-2829. doi: 10.1245/s10434-024-16743-2. Epub 2025 Jan 14.
2
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.术前 mFOLFIRINOX 对比 mFOLFIRINOX 联合短程放疗治疗边界可切除胰腺腺癌的疗效：A021501 期随机临床试验。
JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.
3
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.(m)FOLFIRINOX 新辅助放疗治疗边界可切除胰腺腺癌：TAPS 联盟研究。
J Natl Compr Canc Netw. 2022 Jul;20(7):783-791.e1. doi: 10.6004/jnccn.2022.7008.
4
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.可切除和边缘可切除胰腺癌的新辅助放化疗与 upfront 手术比较：荷兰随机 PREOPANC 试验的长期结果。
J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27.
5
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.吉西他滨新辅助放化疗对比直接手术治疗边界可切除胰腺癌患者的肿瘤学获益：一项前瞻性、随机、开放标签、多中心 2/3 期试验。
Ann Surg. 2018 Aug;268(2):215-222. doi: 10.1097/SLA.0000000000002705.